Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Global Clinical Trials Analysis and Outlook

June 2018 | 36 pages | ID: ND3D20B73CBEN
VPAResearch

Abstracts

Non-Proliferative Diabetic Retinopathy (NPDR) ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Non-Proliferative Diabetic Retinopathy (NPDR) disease clinical trials. The research work analyzes the ongoing Non-Proliferative Diabetic Retinopathy (NPDR) clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Non-Proliferative Diabetic Retinopathy (NPDR) treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials.

Scope of the Report-

• Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials across regions
• Trial information by Phase and Subjects recruited
• Trial information by status, type, sponsor type
• Drugs used for treatment of Non-Proliferative Diabetic Retinopathy (NPDR)
• Both observational and interventional trials analyzed
• Leading companies and universities participating in Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials

Reasons to Buy

• Track competition and design competitive advantages
• Identify right partners to associate with for further research
• Evaluate potential opportunities available in further clinical trials of the disease
• Formulate business development strategies through success rates of clinical trials
• Identify quick markets for recruiting subjects based on trials count by each market

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 KEY FINDINGS, 2018

2.1 Snapshot
2.2 Overview of Non-Proliferative Diabetic Retinopathy (NPDR) Trials

3 CLINICAL TRIALS TRENDS TO 2022

3.1 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Phase
3.2 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Type
3.3 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

4.1 Region wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials
4.2 Top 10 Countries conducting Non-Proliferative Diabetic Retinopathy (NPDR) Trials
4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

5.1 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Sponsor Type
5.2 Non-Proliferative Diabetic Retinopathy (NPDR) Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

6.1 Subjects Recruited for Non-Proliferative Diabetic Retinopathy (NPDR) Trials by year
6.2 Subjects Recruited for Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Phase
6.3 Subjects Recruited for Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Trial Type
6.4 Subjects Recruited for Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase
7.2 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase
7.3 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase
7.4 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials by Country
Figure 2: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials by Phase of Development, 2018
Figure 3: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials by Status, 2018
Figure 4: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials by Type, 2018
Figure 5: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials Split by Region, 2000-2018
Figure 6: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials by Type of Economy, 2018
Figure 7: Non-Proliferative Diabetic Retinopathy (NPDR)- Enrolment by Phase, 2018
Figure 8: Non-Proliferative Diabetic Retinopathy (NPDR)- Enrolment by Trial Type, 2018
Figure 9: Non-Proliferative Diabetic Retinopathy (NPDR)- Enrolment by Recruitment Status, 2018
Figure 10: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials by Sponsor Type, 2018
Figure 11: Non-Proliferative Diabetic Retinopathy (NPDR)- Enrolment by Type of Sponsors
Figure 12: Non-Proliferative Diabetic Retinopathy (NPDR)- Enrolment by Leading Sponsors

List Of Tables

LIST OF TABLES

Table 1: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials by Sponsor Type, 2018
Table 2: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials by Economy Type, 2018
Table 3: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials by Region, 2018
Table 4: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Non-Proliferative Diabetic Retinopathy (NPDR)- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Non-Proliferative Diabetic Retinopathy (NPDR)- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Non-Proliferative Diabetic Retinopathy (NPDR)- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Non-Proliferative Diabetic Retinopathy (NPDR)- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Non-Proliferative Diabetic Retinopathy (NPDR)- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company